Global Cancer Biologics Market 2019-2023
SKU ID : TNV-14160395 | Publishing Date : 17-Apr-2019 | No. of pages : 127
Detailed TOC of Global Cancer Biologics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
Monoclonal antibodies - Market size and forecast 2018-2023
Vaccines - Market size and forecast 2018-2023
Cell and gene therapy - Market size and forecast 2018-2023
Others - Market size and forecast 2018-2023
Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Amgen Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.
PART 14: APPENDIX
Research methodology
List of abbreviations
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Monoclonal antibodies - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Monoclonal antibodies - Year-over-year growth 2019-2023 (%)
Exhibit 21: Vaccines - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Vaccines - Year-over-year growth 2019-2023 (%)
Exhibit 23: Cell and gene therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Cell and gene therapy - Year-over-year growth 2019-2023 (%)
Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Biologics in the pipeline for cancer
Exhibit 42: List of recently approved cancer biologics by the FDA
Exhibit 43: Cancer biologics and their biosimilar versions
Exhibit 44: Impact of drivers and challenges
Exhibit 45: List of collaborations between manufacturers of cancer biologics
Exhibit 46: List of predictive biomarkers for cancer
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Amgen Inc. - Vendor overview
Exhibit 53: Amgen Inc. - Business segments
Exhibit 54: Amgen Inc. - Organizational developments
Exhibit 55: Amgen Inc. - Geographic focus
Exhibit 56: Amgen Inc. - Key offerings
Exhibit 57: Bristol-Myers Squibb Company - Vendor overview
Exhibit 58: Bristol-Myers Squibb Company - Business segments
Exhibit 59: Bristol-Myers Squibb Company - Organizational developments
Exhibit 60: Bristol-Myers Squibb Company - Geographic focus
Exhibit 61: Bristol-Myers Squibb Company - Key offerings
Exhibit 62: Eli Lilly and Company - Vendor overview
Exhibit 63: Eli Lilly and Company - Business segments
Exhibit 64: Eli Lilly and Company - Organizational developments
Exhibit 65: Eli Lilly and Company - Geographic focus
Exhibit 66: Eli Lilly and Company - Segment focus
Exhibit 67: Eli Lilly and Company - Key offerings
Exhibit 68: F. Hoffmann-La Roche Ltd - Vendor overview
Exhibit 69: F. Hoffmann-La Roche Ltd - Business segments
Exhibit 70: F. Hoffmann-La Roche Ltd - Organizational developments
Exhibit 71: F. Hoffmann-La Roche Ltd - Geographic focus
Exhibit 72: F. Hoffmann-La Roche Ltd - Segment focus
Exhibit 73: F. Hoffmann-La Roche Ltd - Key offerings
Exhibit 74: Merck & Co., Inc. - Vendor overview
Exhibit 75: Merck & Co., Inc. - Business segments
Exhibit 76: Merck & Co., Inc. - Organizational developments
Exhibit 77: Merck & Co., Inc. - Geographic focus
Exhibit 78: Merck & Co., Inc. - Segment focus
Exhibit 79: Merck & Co., Inc. - Key offerings
Exhibit 80: Validation techniques employed for market sizing
Keyplayers in Global Cancer Biologics Market 2019-2023
Amgen Inc.Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.